STOCK TITAN

BioNTech SE - BNTX STOCK NEWS

Welcome to our dedicated news page for BioNTech SE (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BioNTech SE.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioNTech SE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioNTech SE's position in the market.

Rhea-AI Summary
BioNTech and DualityBiologics have announced the initiation of a pivotal Phase 3 trial for the next-generation antibody-drug conjugate BNT323/DB-1303 targeting HER2 in patients with metastatic breast cancer. The trial aims to enroll 532 patients at clinical trial sites worldwide, with the primary endpoint being progression-free survival. The Phase 3 trial follows positive Phase 1/2 safety and efficacy data, demonstrating encouraging anti-tumor activity in heavily pretreated patients with HER2-low breast cancer. The collaboration between BioNTech and DualityBio aims to accelerate the development of differentiated antibody-drug conjugate therapeutics for solid tumors, with BioNTech holding commercial rights globally, excluding Mainland China, Hong Kong, and Macau.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
clinical trial
-
Rhea-AI Summary
WuXi Biologics (2269. HK) signs research service agreement with BioNTech SE (Nasdaq: BNTX) to discover two undisclosed targets of preclinical investigational monoclonal antibodies. WuXi Biologics to receive $20 million upfront payment and additional payments for research, development, regulatory, and commercial milestones, as well as tiered royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
none
-
Rhea-AI Summary
WuXi Biologics (2269. HK) signs research service agreement with BioNTech SE (Nasdaq: BNTX) to discover two undisclosed targets of preclinical investigational monoclonal antibodies. WuXi Biologics to receive $20 million upfront payment and additional payments for research, development, regulatory, and commercial milestones, as well as tiered royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.41%
Tags
none
Rhea-AI Summary
BioNTech SE (Nasdaq: BNTX) projects total company revenues of approximately €3 billion for the financial year 2024. The company ended 2023 with approximately €17.5 billion in cash, cash equivalents, and security investments and expects to be commercial-ready by the end of 2025. BioNTech is focusing on expanding its innovative pipeline and has outlined 2024 strategic priorities, including the development of potentially registrational trials and the launch of its first oncology products from 2026 onwards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none
-
Rhea-AI Summary
BioNTech SE (Nasdaq: BNTX) and Duality Biologics (Suzhou) Co. Ltd. announced that the U.S. FDA granted Breakthrough Therapy designation for BNT323/DB-1303, a next-generation antibody-drug conjugate candidate targeting HER2, for the treatment of advanced endometrial cancer. The designation is based on encouraging Phase 1/2 data showing anti-tumor activity and an unconfirmed objective response rate of 58.8% and an unconfirmed disease control rate of 94.1% in heavily pretreated patients with advanced endometrial cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
-
Rhea-AI Summary
BioNTech SE (Nasdaq: BNTX) establishes mRNA vaccine manufacturing site in Kigali, Rwanda, with plans for production of vaccines for infectious diseases and future pandemic preparedness. The facility aims to support equitable access to novel medicines globally and is the first commercial-scale mRNA manufacturing facility on the continent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
Rhea-AI Summary
BioNTech SE (Nasdaq: BNTX) to inaugurate first African site in Kigali, Rwanda, on December 18th, 2023. The event will feature the setup of the first manufacturing unit called BioNTainer, with high-level dignitaries and government representatives in attendance. A live stream will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
none
-
Rhea-AI Summary
BioNTech reports positive clinical data updates and progress in its oncology pipeline. The company also announces successful launches of its COVID-19 vaccine. However, it reduces its 2023 revenue guidance and R&D expenses. For the first nine months of 2023, BioNTech reports revenues of €2.3 billion, net profit of €472 million, and diluted earnings per share of €1.94 ($2.113).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
earnings
-
Rhea-AI Summary
Pfizer and BioNTech announce positive results from Phase 1/2 study of mRNA-based combination vaccine candidates for influenza and COVID-19. Lead formulations show robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. Phase 3 trial to start soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
covid-19
Rhea-AI Summary
BioNTech announces follow-up data from Phase 1/2 trial of CAR-T cell therapy candidate BNT211, showing encouraging signs of clinical activity and increased persistence of cancer-specific CAR-T cells when combined with CARVac.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
clinical trial
BioNTech SE

Nasdaq:BNTX

BNTX Rankings

BNTX Stock Data

22.10B
86.72M
63.98%
18.4%
1.23%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Germany
Mainz

About BNTX

everyone achieves greatness at biontech! as one of the most rapidly growing biotechnology companies in europe, we’re working on revolutionary approaches in the fight against cancer and other diseases. over 400 dedicated, passionate pioneers achieve sensational success and promising breakthroughs time and again by forging new paths – and ensure people all around the world have hope for the future. you too can become a pioneer! http://biontech.de/ http://biontech.de/imprint/